- Home
- VSTM vs ARVN Comparison
VSTM vs ARVN Comparison
Compare VSTM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VSTM | ARVN |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.8M | 781.0M |
| IPO Year | 2012 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VSTM | ARVN |
|---|---|---|
| Price | $7.26 | $12.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 23 |
| Target Price | $13.38 | ★ $18.14 |
| AVG Volume (30 Days) | ★ 1.7M | 866.8K |
| Earning Date | 11-04-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $13,379,000.00 | ★ $312,300,000.00 |
| Revenue This Year | $208.54 | $11.17 |
| Revenue Next Year | $251.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 33.79 | ★ 93.86 |
| 52 Week Low | $4.01 | $5.90 |
| 52 Week High | $11.25 | $20.90 |
Technical Indicators
Market Signals| Indicator | VSTM | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 36.33 | 55.88 |
| Support Level | $6.68 | $11.01 |
| Resistance Level | $8.14 | $12.74 |
| Average True Range (ATR) | 0.57 | 0.53 |
| MACD | -0.11 | -0.07 |
| Stochastic Oscillator | 25.45 | 78.10 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.